Overview of the Safety of Felodipine Based on Clinical Trials in Patients With Hypertension

All clinical studies of at least 1 week's duration with felodipine in patients with hypertension were included in a safety analysis. The major finding was that felodipine does not increase mortality or the incidence of major cardiovascular events and that the data indicate a favorable effect.

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	The American journal of cardiology 1997-04, Vol.79 (7), p.996-999
Hauptverfasser:	Welin, Lennart, Elvelin, Lars, Niklasson, Anne, Olsson, Gunnar, Elmfeldt, Dag
Format:	Artikel
Sprache:	eng
Schlagworte:	Antihypertensive agents Antihypertensive Agents - adverse effects Antihypertensive Agents - therapeutic use Biological and medical sciences Calcium Channel Blockers - adverse effects Calcium Channel Blockers - therapeutic use Cardiovascular disease Cardiovascular system Cerebrovascular Disorders - epidemiology Clinical trials Double-Blind Method Drug therapy Felodipine - adverse effects Felodipine - therapeutic use Female Humans Hypertension Hypertension - drug therapy Hypertension - mortality Male Medical research Medical sciences Middle Aged Myocardial Infarction - epidemiology Pharmacology. Drug treatments Product Surveillance, Postmarketing Prospective Studies Randomized Controlled Trials as Topic
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	All clinical studies of at least 1 week's duration with felodipine in patients with hypertension were included in a safety analysis. The major finding was that felodipine does not increase mortality or the incidence of major cardiovascular events and that the data indicate a favorable effect.
ISSN:	0002-9149 1879-1913
DOI:	10.1016/S0002-9149(97)00034-9